Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid β peptide in mice

Experimental Neurology

Volumn 233, Issue 2, 2012, Pages 767-775

  Santos, Danúbia B ^a   Peres, Kaite C ^a   Ribeiro, Renata P ^a   Colle, Dirleise ^a   Santos, Alessandra A dos ^a   Moreira, Eduardo L G ^a   Souza, Diogo O G ^b   Figueiredo, Cláudia P ^a   Farina, Marcelo ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Amyloid peptide; Cholesterol; Memory; Neuroprotection; Oxidative stress; Probucol; Spatial learning

Indexed keywords

ACETYLCHOLINESTERASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; PROBUCOL; SYNAPTOPHYSIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME REGULATION; HIPPOCAMPUS; LEARNING DISORDER; LIPID PEROXIDATION; MALE; MEMORY DISORDER; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTICHOLESTEREMIC AGENTS; COGNITION DISORDERS; HIPPOCAMPUS; HUMANS; LIPID PEROXIDATION; MALE; MICE; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PROBUCOL; SYNAPSES;

EID: 84856538233     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.11.036     Document Type: Article

References (78)

1. Aburatani H., Matsumoto A., Kodama T., Takaku F., Fukazawa C., Itakura H. Increased levels of messenger ribonucleic acid for apolipoprotein E in the spleen of probucol-treated rabbits. Am. J. Cardiol. 1988, 62:60B-65B.
2. Armstrong R.A. The pathogenesis of Alzheimer's disease: a reevaluation of the "amyloid cascade hypothesis". Int. J. Alzheimers Dis. 2011, 2011:630865.
3. Atack J.R., Perry E.K., Bonham J.R., Perry R.H., Tomlinson B.E., Blessed G., Fairbairn A. Molecular forms of acetylcholinesterase in senile dementia of Alzheimer type: selective loss of the intermediate (10S) form. Neurosci. Lett. 1983, 40:199-204.
4. Axelsen P.H., Komatsu H., Murray I.V. Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease. Physiology (Bethesda) 2011, 26:54-69.
5. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 1997, 18:351-357.
6. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
7. Bridges A.B., Scott N.A., Belch J.J. Probucol, a superoxide free radical scavenger in vitro. Atherosclerosis 1991, 89:263-265.
8. Broadbent N.J., Gaskin S., Squire L.R., Clark R.E. Object recognition memory and the rodent hippocampus. Learn. Mem. 2010, 17:5-11.
9. Butterfield D.A., Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 2002, 32:1050-1060.
10. Carlberg I., Mannervik B. Glutathione reductase. Methods Enzymol. 1985, 113:484-490.
11. Champagne D., Pearson D., Dea D., Rochford J., Poirier J. The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease. Neuroscience 2003, 121:99-110.
12. Cummings B.J., Pike C.J., Shankle R., Cotman C.W. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol. Aging 1996, 17:921-933.
13. Di Paolo G., Kim T.W. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat. Rev. Neurosci. 2011, 12:284-296.
14. Dringen R., Hirrlinger J. Glutathione pathways in the brain. Biol. Chem. 2003, 384:505-516.
15. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 1959, 82:70-77.
16. Ellman G.L., Courtney K.D., Andres V., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7:88-95.
17. Farina M., Campos F., Vendrell I., Berenguer J., Barzi M., Pons S., Sunol C. Probucol increases glutathione peroxidase-1 activity and displays long-lasting protection against methylmercury toxicity in cerebellar granule cells. Toxicol. Sci. 2009, 112:416-426.
18. Figueiredo C.P., Bicca M.A., Latini A., Prediger R.D., Medeiros R., Calixto J.B. Folic acid plus alpha-tocopherol mitigates amyloid-beta-induced neurotoxicity through modulation of mitochondrial complexes activity. J. Alzheimers Dis. 2011, 24:61-75.
19. Garcia-Ayllon M.S., Riba-Llena I., Serra-Basante C., Alom J., Boopathy R., Saez-Valero J. Altered levels of acetylcholinesterase in Alzheimer plasma. PLoS One 2010, 5:e8701.
20. Gotto A.M. The cardiology patient page. Statins: powerful drugs for lowering cholesterol: advice for patients. Circulation 2002, 105:1514-1516.
21. Guardia-Laguarta C., Coma M., Pera M., Clarimon J., Sereno L., Agullo J.M., Molina-Porcel L., Gallardo E., Deng A., Berezovska O., Hyman B.T., Blesa R., Gomez-Isla T., Lleo A. Mild cholesterol depletion reduces amyloid-beta production by impairing APP trafficking to the cell surface. J. Neurochem. 2009, 110:220-230.
22. Haag M.D., Hofman A., Koudstaal P.J., Stricker B.H., Breteler M.M. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry 2009, 80:13-17.
23. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
24. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J. Neurochem. 2009, 110:1129-1134.
25. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
26. Herring A., Lewejohann L., Panzer A.L., Donath A., Kroll O., Sachser N., Paulus W., Keyvani K. Preventive and therapeutic types of environmental enrichment counteract beta amyloid pathology by different molecular mechanisms. Neurobiol. Dis. 2011, 42:530-538.
27. Holzgrabe U., Kapkova P., Alptuzun V., Scheiber J., Kugelmann E. Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin. Ther. Targets 2007, 11:161-179.
28. Hyde L.A., Crnic L.S. Reactivity to object and spatial novelty is normal in older Ts65Dn mice that model Down syndrome and Alzheimer's disease. Brain Res. 2002, 945:26-30.
29. Jeon H., Lee S., Kim T.E., Yoon S.H., Shin S.G., Jang I.J., Yu K.S. Pharmacokinetics and tolerability of probucol after multiple oral administrations in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 2011, 49:688-695.
30. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
31. Kalayci R., Kaya M., Elmas I., Arican N., Ahishali B., Uzun H., Bilgic B., Kucuk M., Kudat H. Effects of atorvastatin on blood-brain barrier permeability during L-NAME hypertension followed by angiotensin-II in rats. Brain Res. 2005, 1042:184-193.
32. Kasai T., Miyauchi K., Kubota N., Kajimoto K., Amano A., Daida H. Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis. Atherosclerosis 2011, 10.1016/j.atherosclerosis.2011.09.051.
33. +-ATPase and acetylcholinesterase in the cortex and hippocampus of rat. Transl. Res. 2011, 157:100-107.
34. Kincses Z.T., Toldi J., Vecsei L. Kynurenines, neurodegeneration and Alzheimer's disease. J. Cell Mol. Med. 2010, 14:2045-2054.
35. Kita T., Nagano Y., Yokode M., Ishii K., Kume N., Narumiya S., Kawai C. Prevention of atherosclerotic progression in Watanabe rabbits by probucol. Am. J. Cardiol. 1988, 62:13B-19B.
36. Lafon-Cazal M., Pietri S., Culcasi M., Bockaert J. NMDA-dependent superoxide production and neurotoxicity. Nature 1993, 364:535-537.
37. Leduc V., Jasmin-Belanger S., Poirier J. APOE and cholesterol homeostasis in Alzheimer's disease. Trends Mol. Med. 2010, 16:469-477.
38. Lee M., Cho T., Jantaratnotai N., Wang Y.T., McGeer E., McGeer P.L. Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB J. 2010, 24:2533-2545.
39. Longenberger J., Shah Z.A. Simvastatin and other HMG-CoA reductase inhibitors on brain cholesterol levels in Alzheimer's disease. Curr. Alzheimer Res. 2011, 8:434-442.
40. Lovell M.A., Xie C., Markesbery W.R. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 1998, 51:1562-1566.
41. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
42. Mattson R.H. Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use. Rev. Neurol. Dis. 2004, 1(Suppl. 1):S10-S17.
43. McLellan M.E., Kajdasz S.T., Hyman B.T., Bacskai B.J. In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J. Neurosci. 2003, 23:2212-2217.
44. Medeiros R., Prediger R.D., Passos G.F., Pandolfo P., Duarte F.S., Franco J.L., Dafre A.L., Di Giunta G., Figueiredo C.P., Takahashi R.N., Campos M.M., Calixto J.B. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J. Neurosci. 2007, 27:5394-5404.
45. Miida T., Takahashi A., Ikeuchi T. Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects. Pharmacol. Ther. 2007, 113:378-393.
46. Moran M.A., Mufson E.J., Gomez-Ramos P. Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains. Acta Neuropathol. 1993, 85:362-369.
47. Mori T., Paris D., Town T., Rojiani A.M., Sparks D.L., Delledonne A., Crawford F., Abdullah L.I., Humphrey J.A., Dickson D.W., Mullan M.J. Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J. Neuropathol. Exp. Neurol. 2001, 60:778-785.
48. Murai T., Okuda S., Tanaka T., Ohta H. Characteristics of object location memory in mice: behavioral and pharmacological studies. Physiol. Behav. 2007, 90:116-124.
49. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95:351-358.
50. Pallebage-Gamarallage M.M., Takechi R., Lam V., Galloway S., Dhaliwal S., Mamo J.C. Post-prandial lipid metabolism, lipid-modulating agents and cerebrovascular integrity: implications for dementia risk. Atheroscler. Suppl. 2010, 11:49-54.
51. Park S.Y., Lee J.H., Kim C.D., Rhim B.Y., Hong K.W., Lee W.S. Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats. Brain Res. 2007, 1157:112-120.
52. Pfuetze K.D., Dujovne C.A. Probucol. Curr. Atheroscler. Rep. 2000, 2:47-57.
53. Piermartiri T.C., Figueiredo C.P., Rial D., Duarte F.S., Bezerra S.C., Mancini G., de Bem A.F., Prediger R.D., Tasca C.I. Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-beta(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage. Exp. Neurol. 2010, 226:274-284.
54. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol. Med. 2003, 9:94-101.
55. Prediger R.D., Franco J.L., Pandolfo P., Medeiros R., Duarte F.S., Di Giunta G., Figueiredo C.P., Farina M., Calixto J.B., Takahashi R.N., Dafre A.L. Differential susceptibility following beta-amyloid peptide-(1-40) administration in C57BL/6 and Swiss albino mice: evidence for a dissociation between cognitive deficits and the glutathione system response. Behav. Brain Res. 2007, 177:205-213.
56. Reaven P.D., Parthasarathy S., Beltz W.F., Witztum J.L. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler. Thromb. 1992, 12:318-324.
57. Regnstrom J., Walldius G., Nilsson S., Elinder L.S., Johansson J., Molgaard J., Holme I., Olsson A.G., Nilsson J. The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Atherosclerosis 1996, 125:217-229.
58. Rockwood K., Kirkland S., Hogan D.B., MacKnight C., Merry H., Verreault R., Wolfson C., McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 2002, 59:223-227.
59. Sberna G., Saez-Valero J., Beyreuther K., Masters C.L., Small D.H. The amyloid beta-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. J. Neurochem. 1997, 69:1177-1184.
60. Scheff S.W., Price D.A., Schmitt F.A., Mufson E.J. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 2006, 27:1372-1384.
61. Schliebs R., Arendt T. The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 2011, 221:555-563.
62. Shankar R., Sallis J.D., Stanton H., Thomson R. Influence of probucol on early experimental atherogenesis in hypercholesterolemic rats. Atherosclerosis 1989, 78:91-97.
63. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
64. Singla D.K., Kaur K., Sharma A.K., Dhingra S., Singal P.K. Probucol promotes endogenous antioxidant reserve and confers protection against reperfusion injury. Can. J. Physiol. Pharmacol. 2007, 85:439-443.
65. Siveski-Iliskovic N., Hill M., Chow D.A., Singal P.K. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995, 91:10-15.
66. Tabner B.J., Turnbull S., El-Agnaf O.M., Allsop D. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic. Biol. Med. 2002, 32:1076-1083.
67. Tabner B.J., Turnbull S., King J.E., Benson F.E., El-Agnaf O.M., Allsop D. A spectroscopic study of some of the peptidyl radicals formed following hydroxyl radical attack on beta-amyloid and alpha-synuclein. Free. Radic. Res. 2006, 40:731-739.
68. Takeda S., Sato N., Niisato K., Takeuchi D., Kurinami H., Shinohara M., Rakugi H., Kano M., Morishita R. Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease. Brain Res. 2009, 1280:137-147.
69. Tanous D., Brasen J.H., Choy K., Wu B.J., Kathir K., Lau A., Celermajer D.S., Stocker R. Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re-endothelialization. Atherosclerosis 2006, 189:342-349.
70. Thinus-Blanc C., Save E., Rossi-Arnaud C., Tozzi A., Ammassari-Teule M. The differences shown by C57BL/6 and DBA/2 inbred mice in detecting spatial novelty are subserved by a different hippocampal and parietal cortex interplay. Behav. Brain Res. 1996, 80:33-40.
71. Ulrich J., Meier-Ruge W., Probst A., Meier E., Ipsen S. Senile plaques: staining for acetylcholinesterase and A4 protein: a comparative study in the hippocampus and entorhinal cortex. Acta Neuropathol. 1990, 80:624-628.
72. Van Beek A.H., Claassen J.A. The cerebrovascular role of the cholinergic neural system in Alzheimer's disease. Behav. Brain Res. 2011, 221:537-542.
73. Verghese P.B., Castellano J.M., Holtzman D.M. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 2011, 10:241-252.
74. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
75. Wendel A. Glutathione peroxidase. Methods Enzymol. 1981, 77:325-333.
76. Yamashita S., Matsuzawa Y. Where are we with probucol: a new life for an old drug?. Atherosclerosis 2009, 207:16-23.
77. Yamashita S., Hbujo H., Arai H., Harada-Shiba M., Matsui S., Fukushima M., Saito Y., Kita T., Matsuzawa Y. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J. Atheroscler. Thromb. 2008, 15:292-303.
78. Zlokovic B.V., Deane R., Sagare A.P., Bell R.D., Winkler E.A. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. J. Neurochem. 2010, 115:1077-1089.